Abstract
Wastewater-based monitoring for SARS-CoV-2 holds promise as tool to inform public health-decision making. Testing at individual building-level could be an efficient, passive means of preventing early detection of new cases in congregate living settings, but this approach has not been validated. Sample collection protocols were developed and refined during preliminary sampling from a hospital and a local municipal wastewater treatment plant. Molecular diagnostic methods were compared side-by-side to assess feasibility, performance and sensitivity. Optimized sample collection and processing protocols were then used to monitor two occupied dormitory complexes (n=105 and 66) over eight weeks. Wastewater results were validated using known case counts from external clinical testing of building occupants. Results confirm that ultracentrifugation from a 24 hour composite collection had a sensitivity of 95% and a specificity of 100%. However, if the detection of convalescent shedding is considered a false positive then the sensitivity would be 95.2% but the specificity would drop to 52%. We determined a highly sensitive method for detecting SARS-CoV-2 shedding in building wastewater however our methods could not distinguish new infectious cases from persistent convalescent shedding of SARS-CoV-2 RNA. Future work must focus on methods to distinguish new infections from convalescent shedding to widely deploy this promising wastewater surveillance tool.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a University of Virginia Engineering in Medicine Seed Grant, and support from the University Reopening Committee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individual patient charts were reviewed to collect the following information: date of initial positive Covid-19 test and date of symptom onset and total tower occupancy (University of Virginia IRB approval# 22521).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data available and is presented in the article without other data repository.
